<DOC>
	<DOCNO>NCT00001905</DOCNO>
	<brief_summary>This study evaluate safety effectiveness drug , interferon gamma , treat leukocyte adhesion deficiency type I ( LAD I ) . Patients inherited immune disorder enough protein call adhesion molecule infection-fighting white blood cell , impair ability cell get site infection . As result , patient recurrent infection soft tissue , skin , gum gastrointestinal tract , poor wound heal . Infants severe LAD I often die multiple infection . Interferon gamma may increase number adhesion molecule white blood cell , thus improve function . Patients LAD I weigh 13 kilogram ( 28.5 pound ) may eligible study . Candidates personal family medical history take , physical examination , blood urine test chest X-ray compute tomography ( CT ) scan . Participants receive injection interferon gamma skin 3 time week 3 month . Adult patient teach give injection ( similar insulin injection diabetes ) parent taught administer shot child . Blood sample , usually 30 90 milliliter ( 2 6 tablespoon ) , draw start medication 1 day , 1 week , 1 month , 3 month 4 month therapy begin . At time interval , patient provide salt-water mouth rinse specimen , test change number white blood cell interferon gamma treatment . Patients admit NIH Clinical Center inpatient evaluation start therapy 1 week , 1month , 3 month 4 month . The initial screening visit take day subsequent visit take 1 2 day .</brief_summary>
	<brief_title>Interferon Gamma Treat Leukocyte Adhesion Deficiency Type I</brief_title>
	<detailed_description>Leukocyte adhesion deficiency type I ( LAD I ) primary immunodeficiency disease result mutation gene encode CD18 . Markedly reduce absent expression leukocyte integrin component CD18 cause significant impairment leukocyte mobilization inflammatory site . Clinically , patient mark leukocytosis recurrent infection involve soft tissue skin , gastrointestinal tract gingiva . Death due infection early infancy common severe form LAD I ( CD18 expression le 0.5 % ) , patient moderate phenotype ( CD18 expression 1-10 % ) may survive young adulthood . To date , therapy consist antibiotic treatment infection bone marrow transplantation possible . LAD I also candidate future gene therapy . Recently , show vivo administration interferon gamma ( IFN-gamma ) upregulates CD18 expression normal alters leukocyte traffic . We hypothesize modest increase CD18 expression LAD I patient moderate phenotype alteration CD18 independent trafficking could result detectable clinical change possible clinical improvement .</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Leukocyte-Adhesion Deficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>PARTICIPANT INCLUSION CRITERIA : Leukocyte Adhesion Deficiency type I , determine flow cytometry show less 10 % CD18 expression association typical sign LAD I . Weight adequate permit blood drawing requirement protocol , great 13 kg . Patients without serious , ongoing , uncontrolled infection . Adequate hematopoietic , renal hepatic function , define : Absolute neutrophil count great equal 1500/microL ; Hemoglobin great equal 7g/dL ( post transfusion erythropoeitin ) ; Platelet count great equal 100,000/microL ; Creatinine le equal 1.5 x upper limit normal ; Bilirubin le equal 1.5 x upper limit normal ; AST/SGOT le equal 2.5 x upper limit normal ; ALT/SGPT le equal 2.5 x upper limit normal ; Calculated Creatinine Clearance great equal 60 mL/min . Karnofsky Performance Status Index great equal 70 . Written sign informed consent . PARTICIPANT EXCLUSION CRITERIA : HIV infection . Active malignancy . Symptomatic cardiac disease ongoing treatment . Pregnant lactating woman . Surgery two week prior start IFNgamma dosing . Concurrent use systemic corticosteroid , except physiologic replacement . Exposure investigational drug within four week prior start dose . Any major illness , investigator 's judgement , may substantially increase risk associate patient participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>Neutrophil</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Treatment</keyword>
	<keyword>Trafficking</keyword>
	<keyword>Leukocyte Adhesion Deficiency Type I</keyword>
	<keyword>LAD I</keyword>
</DOC>